Aadi Bioscience, Inc. (AADI)
NASDAQ: AADI · Real-Time Price · USD
2.880
0.00 (0.00%)
Jan 31, 2025, 4:00 PM EST - Market closed
Company Description
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.
Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Aadi Bioscience, Inc.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 89 |
CEO | David Lennon |
Contact Details
Address: 17383 Sunset Boulevard, Suite A250 Pacific Palisades, California 90272 United States | |
Phone | 424 744 8055 |
Website | aadibio.com |
Stock Details
Ticker Symbol | AADI |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001422142 |
CUSIP Number | 00032Q104 |
ISIN Number | US00032Q1040 |
Employer ID | 61-1547850 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
David J. Lennon Ph.D. | President, Chief Executive Officer and Director |
Scott M. Giacobello CPA | Chief Financial Officer, Treasurer, Investor Relations and Corporate Communications |
Stephen M. Rodin J.D. | Senior Vice President of Legal and General Counsel |
Raymond G. Steitz | Senior Vice President of Human Resources and Chief Human Resources Officer |
Bryan Ball | Chief Technical Operations Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 31, 2025 | DEFM14A | Filing |
Jan 30, 2025 | SCHEDULE 13D | Filing |
Jan 29, 2025 | SCHEDULE 13G | Filing |
Jan 24, 2025 | SCHEDULE 13D/A | Filing |
Jan 21, 2025 | PREM14A | Filing |
Dec 31, 2024 | SCHEDULE 13D | Filing |
Dec 30, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Dec 23, 2024 | SCHEDULE 13D/A | Filing |
Dec 23, 2024 | SCHEDULE 13D/A | Filing |
Dec 20, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |